98%
921
2 minutes
20
Background: Polygenic Risk Scores (PRSs) enable personalisation of cancer risk, supporting risk stratification for melanoma, and colorectal, breast, and prostate cancers. Inclusion of PRS in cancer risk assessment can facilitate risk-appropriate cancer screening by incorporating individuals' age, sex, family history and genomic test results. General Practitioners (GPs) are the likely healthcare professionals to order PRS tests and deliver results to patients within existing preventative health models.
Aim: Elucidate GP perspectives on the use of PRS to tailor cancer screening in the Australian primary care context.
Design And Setting: Thirty GPs were interviewed and were either PRS-naïve or had experience using PRSs in a research context. Participants had a broad spectrum of clinical experience and knowledge of genomics, reflecting the spectrum of experience and knowledge of GPs in Victoria, Australia.
Methods: Inductive and deductive thematic analysis was conducted and aligned to the Consolidated Framework for Implementation Research (CFIR).
Results: Common themes identified general practice being the appropriate setting for PRS-based approaches; personalised approaches to cancer risk can prompt discussions about positive lifestyle changes; and tailored risk reports are useful tools for the communication of complex health information. Barriers identified by GPs included time constraints on the delivery of preventative health care; education requirements to upskill GPs in genomics; possible psychosocial harms to patients identified as being at increased risk; life insurance implications; and added pressure on an already struggling health system.
Conclusion: These findings provide insight into the requirements for implementation of PRSs in primary care, from the perspective of GPs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3399/BJGP.2025.0159 | DOI Listing |
Pathol Res Pract
September 2025
Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address:
Our research aims to ascertain the value of precursor and outgrowth lepidic in aiding the confirmation of multiple lung adenocarcinomas as separate primary lung cancers (SPLC). A total of 151 patients with metachronous multiple invasive adenocarcinomas were included in this study. Driver mutation tests(at least five genes: EGFR, ALK, KRAS, BRAF, and ROS1) were conducted on 302 tumors collected from 151 patients.
View Article and Find Full Text PDFEur J Gastroenterol Hepatol
August 2025
Department of Medical and Surgical Sciences, University of Bologna.
Background: Gastric cancer epidemiology evolved rapidly in the last century, shifting from being one of the main causes of cancer-related death to the sixth in high-income countries.
Methods: We conducted a narrative review on gastric cancer epidemiology. Our review focused on trends of gastric cancer and its relationship with Helicobacter pylori infection; cardia and noncardia gastric cancer risk factors; early onset gastric cancer; second primary cancers in patients with gastric cancer; and implementation of gastric cancer prevention strategies.
Eur J Gastroenterol Hepatol
August 2025
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
Aims: We investigated the independent association between dietary vitamin E intake among individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and all-cause and cause-specific mortality in a representative sample of the USA.
Methods: We used the 2007-2014 US National Health and Nutrition Examination Survey with mortality follow-up through 2019 (median: 8.6 years).
Eur J Gastroenterol Hepatol
September 2025
Background: Prior studies have implicated diabetes as a risk factor for pancreatic cancer, yet the impact of diabetes progression on pancreatic cancer incidence remains unclear. We aim to assess pancreatic cancer risk across different stages of diabetes.
Methods: Employing a predefined search strategy, we conducted a literature review of electronic databases up to 29 February 2024.
JCO Precis Oncol
September 2025
Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.